Related Experiment Video
Updated: Mar 6, 2026

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
Published on: January 12, 2024
Retinopathy in an obesity WHO III cohort: prevalence and risk factors
Juri Mattern1, Alexander Lammert1, Mirko Otto2
15th Medical Department, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany.
Objective:
To assess retinopathy and its risk factors in an obesity WHO III cohort.
Methods:
In the Mannheim Obesity Study, 277 subjects with obesity WHO III aged 18-64 years were examined in a cross-sectional approach. Screening for retinopathy was performed using 3-field retinal photography. Endothelial function was assessed using arteriole-to-venule ratio and flicker light analysis. Subjects with and without retinopathy were analysed for anthropometry, metabolic, vascular and renal parameters.
Results:
Retinopathy was found in 18 of the 277 subjects (6.5%). Prevalence of retinopathy was 16.7% in subjects with and 3.4% in subjects without diabetes mellitus. Between subjects with and without retinopathy there were significant differences in diabetes prevalence (61.1% vs 21.7%, p<0.001), systolic blood pressure (145.56 vs 131.73 mm Hg, p=0.005), intima-media thickness (0.7 vs 0.59 mm, p=0.034), dilatation of retinal veins in response to flicker light (2.24% vs 4.28%, p=0.004) and creatinine (0.92 vs 0.83 mg/dL, p=0.011). Stepwise logistic regression analysis revealed that the presence of diabetes mellitus led to an 8.3-fold increased risk for retinopathy (OR 8.3, p=0.049, 95% CI 1.01 to 67.49), whereas risk for retinopathy decreased by nearly 50% (OR 0.54, p=0.032, 95% CI 0.30 to 0.95) with each percentage increase in venous dilatation in response to flicker light.
Conclusions:
Retinopathy prevalence in our obesity WHO III cohort is low. Presence of diabetes mellitus is the most important risk factor for retinopathy. Preserved venular function indicates protection from retinopathy.
Trial Registration Number:
NCT00770276, Results.
More Related Videos
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Diabetes Mellitus: Type 2 and Gestational
Obesity
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Dosing: Obese Patients
Hypertension III: Clinical Manifestations and Diagnostic Studies

